Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.

10 Sep 2009

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

4 Sep 2009

Two 2008 drug approval reports highlight Ceplene benefits

EpiCept Corporation today announced that Ceplene (histamine dihydrochloride) has been highlighted in two separate reports issued recently reviewing 2008 drug approvals in the European Union.

3 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

Annexin-Vivo 750 imaging agent for measuring cell death in vivo

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Annexin-Vivo 750 imaging agent for measuring and monitoring apoptosis and cell death in vivo.

2 Sep 2009

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

2 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

Hexokinase 2 gene highly expressed in brain metastasis in breast cancer patients

Researchers at the National Cancer Institute have identified a gene that may play a role in breast cancer metastasis to the brain, according to a report in Molecular Cancer Research, a journal of the American Association for Cancer Research.

2 Sep 2009

Research journal to host a webinar on apoptotic signalling in normal and cancer cell biology

The business office of Science, the world's leading peer-reviewed research journal, is producing a webinar on "Apoptotic Signaling in Normal and Cancer Cell Biology" to be broadcast live online at 12 noon ET (4:00 GMT) September 22, 2009, sponsored by Promega.

29 Aug 2009

TRAF6 protein can activate a cell signalling molecule associated with cancer

28 Aug 2009

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase I clinical study of AR-12 (formerly OSU-03012) in adult patients with advanced or recurrent solid tumors or lymphoma.

28 Aug 2009

Study suspects involvement of PPAR-γ in gastric carcinogenesis

Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.

27 Aug 2009

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

The genes that may contribute to drug resistance in non-small cell lung cancer (NSCLC) can be predicted. Researchers writing in the open access journal BMC Cancer found good correlation between genes believed to be involved in drug sensitivity and resistance and actual in vitro chemosensitivity.

26 Aug 2009

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.

26 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Scientists find another mechanism that destroys tumor cells

Cells don't like to be alone. In the early stages of tumor formation, a cell might be pushed out of its normal home environment due to excessive growth. But a cell normally responds to this homeless state by dismantling its nucleus, packing up its DNA, and offering itself to be eaten by immune system cells. Simply put, the homeless cell kills itself. This process, known as apoptosis, typically stops potential cancer cells before they have a chance to proliferate.

20 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.

18 Aug 2009

Disrupting the DNA-repair process

Scientists at Dana-Farber Cancer Institute have uncovered the mechanism behind a promising new approach to cancer treatment: damaging cancer cells' DNA with potent drugs while simultaneously preventing the cells from repairing themselves.

18 Aug 2009

Apoptosis News and Research

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Two 2008 drug approval reports highlight Ceplene benefits

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Annexin-Vivo 750 imaging agent for measuring cell death in vivo

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Hexokinase 2 gene highly expressed in brain metastasis in breast cancer patients

Research journal to host a webinar on apoptotic signalling in normal and cancer cell biology

TRAF6 protein can activate a cell signalling molecule associated with cancer

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Study suspects involvement of PPAR-γ in gastric carcinogenesis

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Scientists find another mechanism that destroys tumor cells

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Disrupting the DNA-repair process

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News